Cessatech, a prominent player in the medical technology sector, has released its financial results for the full year 2025. The company reported net revenues of KDKK 5,718 for the year, with a significant contribution of KDKK 1,989 from the fourth quarter. Despite the revenue growth, Cessatech faced an operating loss of KDKK -14,967 and a net loss of KDKK -10,904 for the year, highlighting ongoing financial challenges.

The company's cash reserves remained stable at KDKK 8,591 by the end of the period, indicating a solid liquidity position. With a solidity ratio of 91%, Cessatech demonstrates a strong equity position relative to its total capital and liabilities, providing a buffer against financial uncertainties.

Strategically, 2025 was a pivotal year for Cessatech. The company announced positive top-line results from Study 0202, the final required pediatric clinical study for CT001. This milestone confirms the safety and efficacy profile of CT001, paving the way for European regulatory submission. Additionally, Cessatech received a positive Notified Body opinion under the EU Medical Device Regulation for CT001, further validating its compliance with safety and performance standards.

In the U.S., Cessatech expanded its collaboration with STAQ Pharma, completing technology transfer activities to support near-term hospital supply. These strategic steps are crucial for Cessatech's market expansion and revenue growth in the coming years.

Furthermore, the company strengthened its financial position through a directed share issue, raising approximately DKK 15 million. The appointment of Martin Juhl as Chief Scientific Officer is expected to enhance the company's executive management, driving further innovation and development.

Given the strategic advancements and stable financial reserves, investors may consider holding Cessatech stock. The company's progress in regulatory approvals and market expansion initiatives suggests potential for future revenue growth and operational improvements.